Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats

Neuropharmacology

Volumn 51, Issue 7-8, 2006, Pages 1129-1136

  Lin, En Ju D ^a   Lee, Nicola J ^a   Slack, Katy ^a   Karl, Tim ^a,b   Duffy, Liesl ^a,b   O'Brien, Elizabeth ^b,c   Matsumoto, Izuru ^c   Dedova, Irina ^b,c   Herzog, Herbert ^a   Sainsbury, Amanda ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b Neuroscience Institute of Schizophrenia and Allied Disorders   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antipsychotic drugs; Endocrine; Glucagon; Haloperidol; Insulin; Risperidone

Indexed keywords

CORTICOSTERONE; GLUCAGON; GONADOTROPIN; GROWTH HORMONE; HALOPERIDOL; HORMONE; INSULIN; LIPID; RISPERIDONE; SOMATOMEDIN BINDING PROTEIN 1; TESTOSTERONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DECREASED APPETITE; ENDOCRINE DISEASE; ENERGY; FOOD INTAKE; FREE THYROXINE INDEX; GLUCAGON BLOOD LEVEL; GLUCOSE TOLERANCE; HOMEOSTASIS AND REGULATION; HYPOPHYSIS ADRENAL SYSTEM; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; METABOLITE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; ANTIPSYCHOTIC AGENTS; APPETITE; BODY WEIGHT; CORTICOSTERONE; DIABETES MELLITUS, TYPE 2; ENDOCRINE SYSTEM; ENERGY INTAKE; GLUCAGON; HALOPERIDOL; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; SPECIES SPECIFICITY; TESTOSTERONE; WEIGHT GAIN;

EID: 33750842955     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.07.006     Document Type: Article

References (60)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. The American Journal of Psychiatry 156 (1999) 1686-1696
2. Allison D.B., Mackell J.A., and McDonnell D.D. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 54 (2003) 565-567
3. Arjona A.A., Zhang S.X., Adamson B., and Wurtman R.J. An animal model of antipsychotic-induced weight gain. Behavioural Brain Research 152 (2004) 121-127
4. Assimacopoulos-Jeannet F., and Jeanrenaud B. The hormonal and metabolic basis of experimental obesity. Clinics in Endocrinology and Metabolism 5 (1976) 337-365
5. Baptista T., de Baptista E.A., Hernandez L., Altemus M., and Weiss S.R. Tamoxifen prevents sulpiride-induced weight gain in female rats. Pharmacology, Biochemistry and Behavior 57 (1997) 215-222
6. Baptista T., Contreras Q., Teneud L., Albornoz M.A., Acosta A., Paez X., de Quijada M., LaCruz A., and Hernandez L. Mechanism of the neuroleptic-induced obesity in female rats. Progress in Neuropsychopharmacology and Biological Psychiatry 22 (1998) 187-198
7. Baptista T., Kin N.M., Beaulieu S., and de Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35 (2002) 205-219
8. Baptista T., Araujo de Baptista E., Ying Kin N.M., Beaulieu S., Walker D., Joober R., Lalonde J., and Richard D. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Research 957 (2002) 144-151
9. Baptista T., Lacruz A., Paez X., Hernandez L., and Beaulieu S. The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?. European Journal of Pharmacology 447 (2002) 91-98
10. Best L., Yates A.P., and Reynolds G.P. Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol. Journal of Psychopharmacology 19 (2005) 597-601
11. Brambilla F., Guerrini A., Guastalla A., Rovere C., and Riggi F. Neuroendocrine effects of haloperidol therapy in chronic schizophrenia. Psychopharmacologia 44 (1975) 17-22
12. Brambilla F., Guastalla A., Guerrini A., Riggi F., Rovere C., Zanoboni A., and Zanoboni-Muciaccia W. Glucose-insulin metabolism in chronic schizophrenia. Diseases of the Nervous System 37 (1976) 98-103
13. Clark C., and Burge M.R. Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technology & Therapeutics 5 (2003) 669-683
14. Conley R.R., and Kelly D.L. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. The Israel Journal of Psychiatry and Related Sciences 42 (2005) 51-60
15. Cope M.B., Nagy T.R., Fernandez J.R., Geary N., Casey D.E., and Allison D.B. Antipsychotic drug-induced weight gain: development of an animal model. International Journal of Obesity 29 (2005) 607-614
16. Cusin I., Terrettaz J., Rohner-Jeanrenaud F., Zarjevski N., Assimacopoulos-Jeannet F., and Jeanrenaud B. Hyperinsulinemia increases the amount of GLUT4 mRNA in white adipose tissue and decreases that of muscles: a clue for increased fat depot and insulin resistance. Endocrinology 127 6 (1990) 3246-3248
17. Eckel R.H. Insulin resistance: an adaptation for weight maintenance. Lancet 340 8833 (1992) 1452-1453
18. Farwell W.R., Stump T.E., Wang J., Tafesse E., L'Italien G., and Tierney W.M. Weight gain and new onset diabetes associated with olanzapine and risperidone. Journal of General Internal Medicine 19 (2004) 1200-1205
19. Feldman P.D., Hay L.K., Deberdt W., Kennedy J.S., Hutchins D.S., Hay D.P., Hardy T.A., Hoffmann V.P., Hornbuckle K., and Breier A. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. Journal of the American Medical Directors Association 5 (2004) 38-46
20. Fell M.J., Neill J.C., and Marshall K.M. Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. European Neuropsychopharmacology 14 (2004) 385-392
21. Fell M.J., Neill J.C., Rao C., and Marshall K.M. Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. Psychopharmacology (Berl) 182 (2005) 499-507
22. Goldstein J.M. The new generation of antipsychotic drugs: how atypical are they?. International Journal of Neuropsychopharmacology 3 (2000) 339-349
23. Green A.I., Patel J.K., Goisman R.M., Allison D.B., and Blackburn G. Weight gain from novel antipsychotic drugs: need for action. General Hospital Psychiatry 22 (2000) 224-235
24. Guillaume-Gentil C., Assimacopoulos-Jeannet F., and Jeanrenaud B. Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia 36 (1993) 899-906
25. Hellewell J.S. A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders. Journal of Psychopharmacology 20 Suppl. 2 (2006) 39-45
26. Henderson D.C. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. The Journal of Clinical Psychiatry 62 Suppl. 23 (2001) 39-44
27. Ho K.K., O'Sullivan A.J., and Hoffman D.M. Metabolic actions of growth hormone in man. Endocrine Journal 43 Suppl. (1996) S57-S63
28. Kanno T., Gopel S.O., Rorsman P., and Wakui M. Cellular function in multicellular system for hormone-secretion: electrophysiological aspect of studies on alpha-, beta- and delta-cells of the pancreatic islet. Neuroscience Research 42 (2002) 79-90
29. Kapur S., and Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry 50 (2001) 873-883
30. Kapur S., and Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. American Journal of Psychiatry 158 (2001) 360-369
31. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. The Journal of Pharmacology and Experimental Therapeutics 305 (2003) 625-631
32. Karl T., Duffy L., O'Brien E., Matsumoto I., and Dedova I. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behavioural Brain Research 171 (2006) 286-294
33. Kato M.M., and Goodnick P.J. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opinion on Pharmacotherapy 2 (2001) 1571-1582
34. Kushi A., Sasai H., Koizumi H., Takeda N., Yokoyama M., and Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 15659-15664
35. Kyle L.H., Ball M.F., and Doolan P.D. Effect of thyroid hormone on body composition in myxedema and obesity. The New England Journal of Medicine 275 (1966) 12-17
36. Liberty I.F., Todder D., Umansky R., and Harman-Boehm I. Atypical antipsychotics and diabetes mellitus: an association. The Israel Medical Association Journal: IMAJ 6 (2004) 276-279
37. Lin Y.W., MacMullen C., Ganguly A., Stanley C.A., and Shyng S.L. A novel KCNJ11 mutation associated with congenital hyperinsulinism reduces the intrinsic open probability of beta-cell ATP-sensitive potassium channels. The Journal of Biological Chemistry 281 (2006) 3006-3012
38. Manzanares J., Canton R., Grande C., Benedi J., and Zaragoza F. Levels of insulin in the brains of rats modified by chronic administration of amphetamine, haloperidol and sulpiride. Neuropharmacology 27 (1988) 1141-1144
39. Marangou A.G., Weber K.M., Boston R.C., Aitken P.M., Heggie J.C., Kirsner R.L., Best J.D., and Alford F.P. Metabolic consequences of prolonged hyperinsulinemia in humans. Evidence for induction of insulin insensitivity. Diabetes 35 (1986) 1383-1389
40. Megens A.A., Awouters F.H., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J., and Leysen J.E. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 114 (1994) 9-23
41. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. European Neuropsychopharmacology 14 (2004) 115-119
42. Miller E.A., Leslie D.L., and Rosenheck R.A. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. The Journal of Nervous and Mental Disease 193 (2005) 387-395
43. Minet-Ringuet J., Even P.C., Guesdon B., Tome D., and de Beaurepaire R. Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behavioural Brain Research 163 (2005) 204-211
44. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10 (2005) 79-104
45. Mudali S., and Dobs A.S. Effects of testosterone on body composition of the aging male. Mechanisms of Ageing and Development 125 (2004) 297-304
46. Nemeroff C.B. Use of atypical antipsychotics in refractory depression and anxiety. The Journal of Clinical Psychiatry 66 Suppl. 8 (2005) 13-21
47. Ota M., Mori K., Nakashima A., Kaneko Y.S., Fujiwara K., Itoh M., Nagasaka A., and Ota A. Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clinical and Experimental Pharmacology & Physiology 29 (2002) 980-989
48. Pedrazzini T., Seydoux J., Kunstner P., Aubert J.F., Grouzmann E., Beermann F., and Brunner H.R. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nature Medicine 4 (1998) 722-726
49. Pierroz D.D., Catzeflis C., Aebi A.C., Rivier J.E., and Aubert M.L. Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats. Endocrinology 137 (1996) 3-12
50. Pouzet B., Mow T., Kreilgaard M., and Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacology, Biochemistry and Behavior 75 (2003) 133-140
51. Rubi B., Ljubicic S., Pournourmohammadi S., Carobbio S., Armanet M., Bartley C., and Maechler P. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. The Journal of Biological Chemistry 280 (2005) 36824-36832
52. Russell J.M., and Mackell J.A. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15 (2001) 537-551
53. Sacchetti E., Turrina C., Parrinello G., Brignoli O., Stefanini G., and Mazzaglia G. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. International Clinical Psychopharmacology 20 (2005) 33-37
54. Sainsbury A., Rohner-Jeanrenaud F., Cusin I., Zakrzewska K.E., Halban P.A., Gaillard R.C., and Jeanrenaud B. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinemia. Diabetologia 40 (1997) 1269-1277
55. Shaw N.J., Fraser N.C., Rose S., Crabtree N.J., and Boivin C.M. Bone density and body composition in children with growth hormone insensitivity syndrome receiving recombinant IGF-I. Clinical Endocrinology 59 (2003) 487-491
56. Standridge M., Alemzadeh R., Zemel M., Koontz J., and Moustaid-Moussa N. Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 14 (2000) 455-460
57. Wadenberg M.L., Soliman A., VanderSpek S.C., and Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25 (2001) 633-641
58. Weiden P.J., Mackell J.A., and McDonnell D.D. Obesity as a risk factor for antipsychotic non-compliance. Schizophrenia Research 66 (2004) 51-57
59. Yang S.B., Proks P., Ashcroft F.M., and Rupnik M. Inhibition of ATP-sensitive potassium channels by haloperidol. British Journal of Pharmacology 143 (2004) 960-967
60. Yoshida H., Itsukaichi O., Saito H., Masuda Y., and Itoh T. Toxicological study on rats fed haloperidol: 80 week chronic toxicity test. The Journal of Toxicological Sciences 20 (1995) 37-46